Climb Bio, INC 8-K filings

Eliem Therapeutics is undergoing a strategic shift, leading to the departure of its Chief Scientific Officer and the appointment of a new principal financial officer.

Eliem Therapeutics has appointed Brett Kaplan as its new Chief Operating Officer, effective August 26, 2024.

Eliem Therapeutics has completed the acquisition of Tenet Medicines and a $120 million private placement, pivoting its focus to developing treatments for autoimmune diseases.

Eliem Therapeutics has completed its acquisition of Tenet Medicines, securing TNT119, an anti-CD19 antibody, and raising $120 million in a private placement to advance its autoimmune disease pipeline.

Eliem Therapeutics' stockholders approved key proposals related to the acquisition of Tenet Medicines and a concurrent private placement at their annual meeting on June 26, 2024.

Eliem Therapeutics has appointed Aoife Brennan as President and CEO, effective upon the closing of the acquisition of Tenet Medicines, and has also added Stephen Thomas to the board.

Eliem Therapeutics will acquire Tenet Medicines, adding a clinical-stage anti-CD19 antibody program for autoimmune diseases, supported by a $120 million private placement.

Eliem Therapeutics is considering acquiring Tango Therapeutics, a private biotech company, in a stock-based transaction as part of a strategic review to maximize shareholder value.